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Background: It is now established that patients with hyperlipidemia have a high risk of atherosclerosis and
thrombotic complications, which are two important events responsible for the onset and progression of
cardiovascular disease. In the context of managing dyslipidemia by means of dietary advice based on the
consumption of argan oil, we wanted to investigate the effect of virgin argan oil on plasma lipids, and for the first
time, on the platelet hyperactivation and oxidative status associated with dyslipidemia. This study concerns patients
recruited in the area of Rabat in Morocco.
Methods: 39 dyslipidemic (79% women) patients were recruited for our study in the area of Rabat in Morocco.
They were randomly assigned to the two following groups: the argan group, in which the subjects consumed
25 mL/day of argan oil at breakfast for 3 weeks, and the control group in which argan oil was replaced by butter.
Results: After a 3-week consumption period, blood total cholesterol was significantly lower in the argan oil group, as
was LDL cholesterol (23.8% and 25.6% lower, respectively). However, the HDL cholesterol level had increased by 26%
at the end of the intervention period compared to baseline. Interestingly, in the argan oil group thrombin-induced
platelet aggregation was lower, and oxidative status was enhanced as a result of lower platelet MDA and higher GPx
activity, respectively.
Conclusions: In conclusion, our results, even if it is not representative of the Moroccan population, show that argan
oil can prevent the prothrombotic complications associated with dyslipidemia, which are a major risk factor for
cardiovascular disease.
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Cardiovascular disease (CVD) is the main cause of in-
creasing mortality worldwide. In 2008, heart disease
accounted for 23% of deaths in Morocco [1]. Dys-
lipidemia, the main risk factor for CVD, is a heteroge-
neous metabolic disorder involving multiple etiologies; it
is commonly characterized by increased triglycerides, low-* Correspondence: nadia_meskini@hotmail.com
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reproduction in any medium, provided the ordensity lipoprotein (LDL) cholesterol and apolipoprotein
B (apo-B) levels, and reduced plasma high-density lipo-
protein (HDL) cholesterol [2]. These components of
dyslipidemia confer an increased risk for atherosclerosis
and thrombosis, which are two important events respon-
sible for the onset and progression of CVD [3]. It is now
established that patients with hyperlipidemia have a high
risk of atherosclerosis and thrombotic complications [4-6].
Several mechanisms have been suggested by which alter-
ations in plasma lipid levels may promote atherosclerosis
[7-9]. One major determinant of the prothrombotic state
associated with hypercholesterolemia appears to be relatedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.lipidworld.com/content/12/1/107to enhanced platelet activation. Indeed, platelets are
known to play a fundamental role in atherogenesis and in
the pathology of atherothrombotic disorders [10]. In-vivo
platelet activation has been reported in type-IIa hypercho-
lesterolemic patients [11], suggesting that high levels of
oxidized LDL, via changes in the composition of platelet
membrane phospholipids and cholesterol, may increase
the platelet reactivity associated with enhanced thromb-
oxane A2 (TxA2) biosynthesis. The involvement of blood
platelet activation in the onset of atherosclerosis is well
established. It has long been recognized that platelets are
involved in the late thrombotic complications of athero-
sclerosis plaque due to erosion of the endothelium or rup-
ture of the fibrous cap that covers the lipid core within the
plaque [12]. The association of platelet activation with
acute CVD justifies anti-platelet therapy as a standard
treatment for those at high risk of atherothrombosis.
Several epidemiological, clinical, and experimental stud-
ies have established that diet can have beneficial effects on
the cardiovascular system, and can therefore be consid-
ered to provide an effective therapeutic tool for preventing
several CVD risk factors, such as dyslipidemia, platelet
hyper-reactivity, and diabetes [13,14]. As far as ingested
lipids are concerned, the influence of their quality and
quantity has often been demonstrated in human and ani-
mal models [15]. Haimeur et al. [16] showed that a high
fat diet consumption increased the incidence of CVD in
rats, by increasing blood lipids level, platelet aggregation
and hepatic oxidative stress, however these risk factors of
CVD were lower in rats fed with a high fat diet
supplemented with a freeze-dried of Odontella aurita, a
marine diatom rich in omega-3 (eicosapentaenoic acid)
and antioxidants molecules.
Argan oil is a natural vegetable oil that has been widely
used in both the daily diet and folk medicine in
Morocco. It is extracted from the kernels of Argania
spinosa, an endemic tree growing in the south-western
region of Morocco. The main traditional use of this ed-
ible oil is for nutritional purposes by consuming it dir-
ectly on toast, generally during breakfast [17]. This oil is
rich in unsaturated fatty acids (80%) principally oleic and
linoleic acids (44.8% and 33.7%, respectively) [18]. Inter-
estingly, the unsaponifiable fraction of argan oil (1% of
the oil constituents) contains mainly antioxidant com-
pounds, such as tocopherols, especially γ-tocopherol,
which are present in higher portions than in olive oil
(637 mg/kg versus 258 mg/kg of total tocopherols, re-
spectively) (Table 1) [18]. As could be expected from its
interesting composition, argan oil has demonstrated its
pharmacological effects in several studies. Initially demon-
strated in rats [19-22], the hypocholesterolemic potency of
argan oil in humans has also been demonstrated by a co-
hort study of 60 healthy men [23]. Numerous nutritional
studies have also shown that argan oil lowers LDLcholesterol and has antioxidant properties; these proper-
ties have been demonstrated in a cohort study involving
96 people [24]. Here, the subjects who consumed argan
oil on a regular basis presented with significantly lower
levels of plasma LDL cholesterol and lipoprotein A Lp (a),
and lower levels of plasma lipoperoxides (thiobarbituric
acid reactive substances, TBARS) [24]. Argan oil also in-
creases HDL cholesterol and lowers triglyceride levels in
men [25], and therefore regular argan oil consumption
could potentially prevent diabetes [26]. Furthermore,
when rats were fed for 4 weeks with 10 mL/kg/day of
argan oil, the thrombin-induced aggregation of isolated
platelets was significantly inhibited (36%), however, the
tail bleeding time remained unchanged [27]. Recently,
Mekhfi et al. [28] have reported that argan oil has
antithrombotic activity in rats, which could be related to
its antiplatelet rather than its anticoagulant activity.
Argan oil has already been reported to be a hypo-
lipidemic factor in both human and animal models with-
out producing any adverse effects [20,24]. However, the
anti-aggregant effect of argan oil has so far only been de-
scribed in-vitro in rats [27]. Thus the originality of the
study reported here, is investigating the protective effect
of argan oil against platelet disorders, such as hyper-
activity and oxidative stress in dyslipidemic patients.
According to the low sampling of patient recruited in
the area of the city of Rabat, our exploratory study is not
significant of the moroccan population.
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Patients
This study was conducted on dyslipidemic patients attend-
ing the Endocrinology Department of the Ibn Sina Univer-
sity Hospital, Rabat, Morocco. The inclusion criteria was
patients with hypercholesterolemia or/and hypertriglyc-
eridemia. The exclusion criteria included myocardial in-
farction, the presence of hepatic or renal disease, the use of
anti-aggregant drugs (aspirin, thienopyridines) or of lipid-
lowering drugs (statins), unusual diet (low or high fat or
carbohydrate diets), or taking hormone therapy during the
previous 6 months. The protocol and objectives of this
study were explained to the participants in detail. Before
the recruitment, patients give their consent orally. The
study protocol was approved by the Institutional Ethics
Committee of the Endocrinology, Diabetology, and Nu-
trition Department, Ibn Sina University Hospital, Rabat,
Morocco. Among the 78 patients who consulted, a total of
39 dyslipidemic patients were selected on the basis of the
inclusion criteria. All the patients included underwent a
thorough physical examination in the Service at 3 consulta-
tions during the study.
Study design
This study was conducted according to the protocol de-
scribed by Derouiche et al. [25]. The study design consisted
of two diet periods. The first diet period (stabilization
period) lasted 2 weeks during which all the patients con-
sumed 20 g/day of butter on toasted bread for breakfast,
and both argan oil and olive oil were eliminated from their
diet. This stabilization period was intended to ensure that
all the patients had a similar fat intake and stable dys-
lipidemia parameters before starting the study. In the sec-
ond diet period (nutritional intervention), which lasted 3
weeks, the patients were randomly assigned to one of two
groups: the first group (18 patients) received the 20 g/day
butter diet (control group: C); the second group (21 pa-
tients) received 25 mL/day of virgin argan oil instead of the
butter with the toasted bread for breakfast (argan oil group:
AO). The daily eating habits of all the patients were inves-
tigated by means of a comprehensive food questionnaire
covering all foods commonly consumed in Morocco. Dur-
ing the nutritional intervention period, all patients followed
a lifestyle and diet recommended by the guidelines for the
management of dyslipidemia [29]. The argan oil supplied
to the patients was all purchased from the same source,
and was extracted by an industrial process [30].
Blood collection
During the study, the patients provided 3 blood samples.
The first was collected intravenously in vacuum tubes after
they had fasted for 12 h, and was used to confirm their
dyslipidemia by serum lipid analysis. At the end of the
stabilization period, the second sample was collectedintravenously into two tubes: the first was a vacuum tube
containing EDTA, and this blood was used for serum lipid
analysis, and the other was a tube containing citric phos-
phate dextrose (CPD) anticoagulant (citric acid: 15.6 mM;
sodium citrate: 89.4 mM, monosodium phosphate: 16.1
mM and dextrose: 128.7 mM) in a ratio of 1/7 v/v CPD/
blood, and this was used for platelet analysis (platelet aggre-
gation test, basal TxB2 determination and platelet oxidative
status). The third blood sample was similar to the second
and was collected at the end of the nutritional intervention.
Anthropometric and serum lipid parameters
Demographic and anthropometric parameters (age, sex,
weight, body mass index (BMI), blood pressure) were
recorded for the patients at baseline. Serum total choles-
terol (TC) and HDL-cholesterol levels were determined
using commercial enzymatic kits (Randox cholesterol en-
zymatic kit and Randox HDL cholesterol precipitant for
cholesterol and HDL-cholesterol, respectively, Crumlin, Co.
Antrim, UK) according to Richmond’s colorimetric proce-
dure [31]. Serum triglyceride levels were determined using
a commercial kit (Randox, Triglyceride Enzymatic Kit,
Crumlin, Co. Antrim, UK) according to Trinder’s colori-
metric method [32]. The LDL-cholesterol level was calcu-
lated by Friedewald’s formula [33]. LDL cholesterol (g/L) =
total cholesterol (g/L) – HDL cholesterol (g/L) – triglycer-
ides/5 (g/L).
Platelet aggregation
Platelets were isolated as previously described by Lagarde
et al. [34]. Briefly, blood was centrifuged at 200 x g for
15 min at 20°C to obtain platelet-rich plasma (PRP). PRP
was then acidified to pH 6.4 with 0.15 M citric acid, and
immediately centrifuged at 900 x g for 10 min at 20°C.
Platelet pellets were resuspended in Tyrode/HEPES buffer
solution (137 mM NaCl, 2.7 mM KCl, 11.9 mM NaHCO3,
0.41 mM NaH2PO4, 1 mM MgCl2, 5.5 mM glucose,
5.0 mM HEPES, pH 7.35). Platelet concentration was ad-
justed to 300 000 /μL before aggregation assay. The isolated
platelets were then used to determine platelet aggregation
by turbidimetry [35] using a PACKS 4 aggregometer (HEL-
ENA, TX, USA). Aggregation tests were performed at 37°C
in cuvettes stirred at 1000 rpm. Isolated platelets were
stimulated by exposure to thrombin (Sigma-Aldrich, Saint-
Quentin Fallavier, France) 0.2 U/mL. The light transmission
was recorded for 3 min after platelet stimulation. The plate-
let aggregation was quantified from the maximum change
in light transmission through a washed platelet suspension,
expressed as a percentage of the light transmission through
the blank (Tyrode buffer).
Platelet MDA measurement
Platelet lipid peroxidation was evaluated by measuring the
malondialdehyde (MDA) level according to the method
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were added 100 μL of 8.1% sodium dodecyl sulfate (SDS),
750 μL of acetic acid 20% at pH 3.5, 750 μL of thio-
barbituric acid (TBA) 0.8%, and distilled water to make up
the volume to 2.5 mL. The tubes were maintained in a
water bath at 95°C for 60 min. The tubes were then imme-
diately cooled in ice. 500 μL of distilled water and 2.5 mL
of a solution of n-butanol and pyridine (15:1 v/v) were
then added to each tube. The tubes were shaken vigor-
ously before being centrifuged at 1000 x g for 10 min. The
organic phase, corresponding to the upper layer, was
aspirated and its color intensity measured at 532 nm. A
standard range was prepared using a 1,3,3,3- tetra-
methoxypropane (Sigma-Aldrich, Saint-Quentin Fallavier,
France) solution.Platelet glutathione peroxidase activity
The glutathione peroxidase (GPx) activity was determined
in isolated platelets according to the Paglia and Valentine
method [37], as modified by Chaudiére and Gérard [38].
Briefly, 100 μL of platelet lysate was added to a final vol-
ume of 1.5 mL of a solution containing Tris-HCl/EDTA
(50 mM/0.1 mM) pH 7.6, NADPH, H+ (0.14 mM), re-
duced glutathione (GSH) (2 mM) and 0.7 U/mL of GSSG-
reductase. The mixture was incubated at 37°C for 3 min.
The reaction was started by adding 50 μL tertiary butyl
hydroperoxide (t-BH) (0.2 mM). The change in absorb-
ance was recorded at 340 nm for 5 min at 5 s intervals.
An appropriate control without the platelet sample was
run simultaneously. GPx activity was expressed in nmoles
of hydroperoxide reduced per min and per mg protein.Table 2 Baseline anthropometrical and biologicalThromboxane B2 measurement
To determine the platelet thromboxane B2 (TxB2) level,
isolated platelets were subjected to three successive
freeze/thaw cycles to release the cell contents. The base-
line TxB2 level was measured by enzyme immunoassay
(EIA) Kit (Enzo-Life Sciences, Exeter, U.K) according to
the Manufacturer’s instructions.characteristics of the study groups
Characteristic Control group Argan oil group
Sex (W/M) 14/4 17/4
Age (years) 51 ± 9 55 ± 8
Weight (Kg) 74.9 ± 13.0 72.3 ± 9.4
SBP (mmHg) 11.9 ± 1.3 12.4 ± 0.9Assay of proteins
Platelet total proteins were determined by the Bradford
colorimetric method [39] using Biorad reagent and bo-
vine serum albumin as standard (Sigma-Aldrich, Saint-
Quentin Fallavier, France).DBP (mmHg) 6.7 ± 0.9 6.9 ± 0.7
BMI (Kg/m2) 29.6 ± 5.0 29.7 ± 4.9
TC (g/L) 2.53 ± 0.3 2.41 ± 0.4
TG (g/L) 1.62 ± 0.1 1.73 ± 0.2
HDL-chl (g/L) 0.45 ± 0.07 0.50 ± 0.05
LDL-chl (g/L) 1.13 ± 0.2 1.35 ± 0.3Statistical analysis
All values were expressed as the mean ± SD. After ana-
lysis of variance, the mean values were compared using
Fisher's least significant difference test (Statgraphics Plus
5.1, Manugistics Inc., Rockville, MD, USA). P < 0.05 was
accepted for significant differences.Results
Baseline anthropometric parameters
The baseline characteristics of the patients, including
their sex and age as well as the risk factors associated
with atherosclerosis diseases, are presented in Table 2. At
the beginning of the intervention period, the data showed
that both groups displayed abnormal blood lipid markers
characterized by hypercholesterolemia and hypertriglyc-
eridemia. According to the International Diabetes Feder-
ation (IDF) definition [40], all of the patients exhibited at
least two components of metabolic syndrome (MS). In
addition to hypertriglyceridemia and hypercholesterol-
emia, the most frequent component of the MS in our pa-
tients was central obesity.
Serum lipid parameters
After the three weeks of the nutritional intervention
period, a significant improvement in atherogenic lipid pa-
rameters was found in the AO group patients as compared
to the values found before the nutritional intervention
period (Figure 1). The data showed significantly (p = 0.04)
lower total cholesterol and LDL-cholesterol levels (p =
0.02) and significantly (p = 0.01) higher HDL-cholesterol
levels in the group consuming argan oil than in the control
group of patients (23.8% versus 13.5%, 25.6% versus 10.4%,
and 26% versus 6.6%, respectively). However, there was no
difference in triglyceride levels between the two groups
after the three weeks of the intervention period.
Platelet aggregation and TxB2 production
Platelet hyperactivity is associated with an increase risk of
adverse cardiovascular outcomes. We evaluated the plate-
let function of patients by studying the platelet response
to aggregation agonist stimulation. The thrombin-induced
aggregation exemple is shown in the Figure 2. The results
obtained after the three weeks of the nutritional interven-
tion period showed that the percentage thrombin-induced
platelet aggregation was significantly (p = 0.03) lower in
CAO










Figure 1 Variations in different plasma lipid markers after 3
weeks of nutritional intervention with argan oil. Data are the
percentage variation of the lipid parameters between the two
periods. Comparisons are made between the variation in the two
groups of patients (C: control group; AO: argan oil group). TC: total
cholesterol; TG: triacylglycerol ; HDL-Chl : high density lipoprotein
cholesterol; LDL-Chl: low density lipoprotein cholesterol. After a
one-way ANOVA, Student-Newman-Keuls multiple test, a
comparison was made between the two groups of patients.
***: p = 0.01; **: p = 0.02; *: p = 0.04.
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62.6%) at the end of the intervention period (Figure 3).
On another hand, the baseline concentration of TxB2,
the stable catabolite of TxA2, tended to be lower in the
AO group than in the control group after the three weeks
of the intervention period, but this difference was not sta-
tistically significant (p = 0.1) (Figure 4).
Platelet oxidative status
The results for the platelet oxidative status are shown in












A: argan oil group
Figure 2 Original traces showing effect of argan oil on platelet aggre
thrombin. before: before treatment; after: after treatment.period, the data showed that platelet lipid peroxidation
levels were lower in patients consuming argan oil, with an
MDA level about 34% lower (p = 0.02) than in the control
group at the end of the intervention period (Figure 5).
This result was correlated with the activity of platelet
GPx, the main enzyme catalyzing the reduction of lipid
hydroperoxides to the corresponding alcohols (Figure 6).
Interestingly, at the end of the intervention period, the
platelet GPx activity in the AO group increased by 22%
(p = 0.02) when compared to the control group.
Discussion
Hypercholesterolemia and platelet hyperactivity are asso-
ciated with an increased risk of adverse cardiovascular
outcomes (coronary artery disease, hypertension). Argan
oil is rich in unsaturated fatty acids, and also contains a
non-glyceride fraction characterized by the presence of
sterols and antioxidant components, which gives it inter-
esting biological and pharmacological properties. The
present investigation was undertaken to assess the poten-
tial platelet anti-aggregant and antioxidant effects of argan
oil on dyslipidemic patients. This clinical study involved
evaluating the effects of argan oil after a three-week period
during which consuming argan oil on toasted bread for
breakfast was compared with consuming butter on toasted
bread.
Interestingly, our results showed that argan oil appeared
to be effective in preventing hypercholesterolemia in
dyslipidemic patients. They show that after three weeks of
argan oil consumption, circulating total cholesterol and
LDL-cholesterol lowered by about 24% and 25%, respect-
ively, compared to the values obtained before the nutrition




























Figure 3 Platelet aggregation after 3 weeks of nutritional
intervention with argan oil. Washed platelets were stimulated
with thrombin (0.2 U/ml). Comparisons are made between the %
platelet aggregation before and after the intervention period in the
two groups. C: control group; AO: argan oil group. After a one-way
ANOVA, Student-Newman-Keuls multiple comparison test, results are




























Figure 5 Platelet malondialdehyde (MDA) level after 3 weeks of
nutritional intervention with argan oil. Comparisons are made
between the platelet MDA level before and after the intervention
period in the two groups. C: control group; AO: argan oil group.
After a one-way ANOVA, Student-Newman-Keuls multiple
comparison test, results are arranged in increasing order from left to
right a > b (p < 0.05).
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control patients. However, argan oil had no effect on cir-
culating triglyceride levels after three weeks of interven-
tion, whereas Derouiche et al. [25] reported that plasma
triglyceride levels decreased significantly by 17.5% in
healthy people consuming about 28 mL/day of argan oil
over a 3-week period. Indeed, a lipid-lowering effect of
argan oil has been reported in several other studies involv-
ing either animals or healthy male subjects [41-43], but
our results demonstrate for the first time the hypo-
cholesterolemic effect of argan oil on dyslipidemic pa-
tients. There is now abundant evidence that diets high in
unsaturated fatty acids have a hypocholesterolemic effect
when substituted for diets high in saturated fatty acids
[44,45]. This has been showed by the beneficial effects of
the “Mediterranean diet”, which is attributed, besides the



























Figure 4 Platelet thromboxane B2 (TxB2) level after 3 weeks of
nutritional intervention with argan oil. Comparisons are made
between the platelet TxB2 level before and after the intervention
period in the two groups. C: control group; AO: argan oil group.
After a one-way ANOVA, Student-Newman-Keuls multiple
comparison test, results are arranged in increasing order from left to
right a > b (p < 0.05).etc, to its high content of olive oil, which is an important
source of monounsaturated fatty acids (MUFAs) (73% of
oleic acid), whereas sunflower oil has a high content of
polyunsaturated fatty acids (PUFAs) (61.6% of linoleic
acid) [46]. However, argan oil is also characterized by
containing balanced proportions of MUFAs and PUFAs
(44.8% oleic acid and 33.7% linoleic acid) [18]. Linoleic
acid (C18: 2n − 6) is an essential fatty acid, and is a pre-
cursor in the biosynthesis of arachidonic acid (C20: 4n −
6). Arachidonic-derived fatty acids, particularly γ-linolenic
acid, are known to reduce the total cholesterol, VLDL, and
LDL-cholesterol levels in human and rat serum [47,48]. In
addition to unsaturated fatty acids, other minor compo-
nents of argan oil, such as plant sterols, may also be impli-
cated in the hypocholesterolemic effect of this oil.






























Figure 6 Platelet glutathione peroxidase (GPx) activity after 3
weeks of nutritional intervention with argan oil. Comparisons
are made between the platelet GPx activity before and after the
intervention period in the two groups. C: control group; AO: argan
oil group. After a one-way ANOVA, Student-Newman-Keuls multiple
comparison test, results are arranged in increasing order from left to
right a > b (p < 0.05).
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carbon-22. These features increase their hydrophobicity
and reduce their absorption [49]. Phytosterols compete
with endogenous cholesterol for space within bile salt mi-
celles in the intestinal lumen, thereby reducing cholesterol
absorption [50,51]. A recent, randomized, placebo-con-
trolled, crossover trial reported that incorporating softgel
capsules containing esterified plant sterols/stanols 1.8 g/
day into the National Cholesterol Education Program
(NCEP) Therapeutic Lifestyle Changes diet, produced fa-
vorable changes in atherogenic lipoprotein and cholesterol
levels in subjects with hypercholesterolemia [52]. These
results corroborate those found in several studies con-
ducted with argan oil [25,41-43]. Furthermore, the cho-
lesterol-lowering effect of argan oil observed in our study
could be related to a synergistic effect of unsaturated fatty
acids and sterols, the main constituents of this oil.
Accumulating evidence indicates that oxidative stress
plays a significant role in the onset of atherosclerosis [53],
and that platelet activation is an important contributing
factor in the process of atherosclerosis and its thrombotic
complications. In this study, we investigated the effect of
argan oil on platelet aggregation, TxB2 release, and platelet
oxidative status in dyslipidemic patients. Our results
showed that argan oil produced an anti-aggregant effect
after it had been consumed for three weeks instead of
butter at breakfast. This anti-aggregant effect was demon-
strated by a 29% decrease in thrombin-induced aggrega-
tion and a tendency towards lower baseline TxB2 levels in
the AO group than in controls. In-vitro, an inhibition of
thrombin- or epinephrine-induced aggregation by up to
50% was obtained in isolated rats platelets with a dose of
0.5% of argan oil [27]. At least two mechanisms are prob-
ably involved by which the fatty acids regulate platelet
function: modulation of the pool of precursor fatty acids
and their competitors, with subsequent effects on eicosa-
noid metabolism, and changes in cell membrane fluidity,
resulting in changes in the activity and/or efficiency of
platelet agonist receptors [54,55]. The chemical compos-
ition of argan oil is dominated by unsaturated fatty acids
(80%), principally oleic and linoleic acids. These unsatur-
ated fatty acids are known to be precursors of pro-
thrombotic and pro-inflammatory eicosanoids; so the
anti-aggregant effect observed could be related to the
unsaponifiable fraction of argan oil (1% of the oil constitu-
ents), which is richer in tocopherols than olive oil. It also
contains other important compounds, such as phenols,
principally ferulic and syringic acids, which have already
been reported to be anti-aggregants [56]. However, several
studies have related the anti-aggregant effect of linoleic
acid to the synthesis of prostaglandins E1 (PGE1) and
prostacyclins I2 (PGI2), which share the same receptor in
platelet membranes and inhibit platelet aggregation by in-
creasing cyclic AMP (cAMP) through the activation ofreceptor-linked adenylate cyclase [57,58]. Furthermore,
most oxidant-induced alterations are influenced by the na-
ture of the cellular redox status. It is known that the
increased lipid peroxidation observed in some redox-
sensitive pathological states (such as dyslipidemia and dia-
betes) [59] is closely associated with impairment of the
antioxidant defenses against peroxides, i.e. decreased ac-
tivity of GPx [60], the main enzyme that catalyzes the re-
duction of lipid hydroperoxides to the corresponding
alcohols. The results obtained on the platelet oxidative
status showed an antioxidant effect of argan oil after three
weeks of intervention. This antioxidant effect was mani-
fested by lower platelet MDA levels and higher platelet
GPx activity in patients who had consumed argan oil for
three weeks compared to control patients who had not. In
spite of the high antioxidant content of argan oil, little is
known about its mechanism of action. In-vitro investiga-
tions of the antioxidant effect of argan oil have reported
that incubating LDL with tocopherols, sterols, and phen-
olic extracts of argan oil significantly prolonged the lag-
phase of LDL peroxidation [61]. Also, phenolic extracts
have been shown to lower the rate of lipid peroxidation,
and reduce the disappearance of vitamin E in a con-
centration-dependent manner [61]. Other ex-vivo studies
have investigated whether the consumption of argan oil
could improve antioxidant status in healthy male subjects
[23]. Indeed, polyphenols, tocopherols, and sterols could
all act as powerful antioxidants via several mechanisms:
scavenging of peroxy radicals that break the peroxidation
chain reaction; chelating free Cu2+ to form redox-inactive
complexes, thus reducing metal-catalyzed oxidation; and
inhibiting the binding of Cu2+ to apolipoproteins and sub-
sequently preventing the modification of the amino acid
apo-B protein residue [62].
In conclusion, our study shows that argan oil intake for
a period of three weeks reduces the risk factors for
prothrombotic complications by decreasing plasma chol-
esterol levels and preventing the platelet hyperactivity and
oxidative stress associated with dyslipidemia. Despite the
limitations of our study due to the difficulty of collecting
sufficient blood to perform all the platelet analysis, these
new data are of considerable relevance to the management
of dyslipidemia, which is a major risk factor for CVD. Fi-
nally, argan oil could be part of the dietary advice provided
in the context of the nutritional management of athero-
sclerotic CVD.Abbreviations
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